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Abstract (250 of 250 words).  
Background. Smoking prevalence is higher amongst individuals with schizophrenia and 
depression compared to the general population. Mendelian randomisation (MR) can 
examine whether this association is causal using genetic variants identified in genome-wide 
association studies (GWAS).  
Methods. We conducted two-sample Mendelian randomisation to explore the bi-directional 
effects of smoking on schizophrenia and depression. For smoking behaviour, we used 1) 
smoking initiation GWAS from the GSCAN consortium and 2) we conducted our own GWAS 
of lifetime smoking behaviour (which captures smoking duration, heaviness and cessation) 
in a sample of 462,690 individuals from the UK Biobank. We validated this instrument using 
positive control outcomes (e.g., lung cancer). For schizophrenia and depression we used 
GWAS from the PGC consortium.  
Results. There was strong evidence to suggest smoking is a risk factor for both 
schizophrenia (OR= 2.27, 95% CI = 1.67 - 3.08, P < 0.001) and depression (OR= 1.99, 95% 
CI = 1.71 - 2.32, P < 0.001). Results were consistent across both lifetime smoking and 
smoking initiation. We found some evidence that genetic liability to depression increases 
lifetime smoking (β= 0.091, 95% CI = 0.027 - 0.155, P = 0.005) but evidence was mixed for 
schizophrenia (β= 0.022, 95% CI = 0.005 - 0.038, P = 0.009) with very weak evidence for an 
effect on smoking initiation.  
Conclusions. These findings suggest that the association between smoking, schizophrenia 
and depression is due, at least in part, to a causal effect of smoking, providing further 
evidence for the detrimental consequences of smoking on mental health.   
 







 Smoking is a major risk factor for lung cancer, cardiovascular and respiratory 
diseases making it the leading cause of preventable death worldwide (World Health 
Organization, 2011). In developed nations, smoking is more common amongst individuals 
with mental health conditions (Coulthard et al., 2002; Lasser et al., 2000; Lawrence et al., 
2009; McClave et al., 2010), in particular schizophrenia (Royal College of Physicians, 2013) 
and depression (Byers et al., 2012; Leung et al., 2011; Tjora et al., 2014). In the UK, 
estimates suggest that up to 45% of individuals with schizophrenia, and 31% of individuals 
with depression smoke (Royal College of Physicians, 2013), compared to around 15% of the 
general population (ONS, 2018). Individuals with mental health conditions smoke more 
heavily (Coulthard et al., 2002) and experience up to 18 years reduced life expectancy 
compared with the general population (Chang et al., 2011; Royal College of Physicians, 
2013). Much of this reduction can be explained by smoking related diseases (Royal College 
of Physicians, 2013), making it important to understand the relationship between smoking 
and mental health. 
 It is often assumed that the association between mental health and smoking can be 
explained by a self-medication model – that is, symptoms of mental illness, or side effects of 
psychiatric medications, are alleviated by the chemical properties of tobacco (Desai et al., 
2001; Khantzian, 1997; Lerman et al., 1996; Levin et al., 1996). However, observational 
evidence cannot determine whether the association between smoking and mental health is 
causal or the result of confounding (Lawlor et al., 2008). Furthermore, traditional 
observational evidence cannot robustly identify the direction of causation (Lawlor et al., 
2008), and there is growing evidence to suggest that smoking may be a causal risk factor for 
poor mental health. The genome-wide association study (GWAS) of schizophrenia 
conducted by the Psychiatric Genomics Consortium (PGC) found that variants in the gene 
cluster CHRNA5-A3-B4 were associated with increased schizophrenia risk (Ripke et al., 
2014). These variants are known to be strongly associated with heaviness of smoking 
(Munafò et al., 2012; Thorgeirsson et al., 2008; Tobacco Consortium, 2010; Ware et al., 
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2011). Therefore, one interpretation is a causal effect of smoking on schizophrenia (Gage 
and Munafò, 2015). Furthermore, there is evidence of genetic correlations between smoking, 
schizophrenia and depression (Hartz et al., 2018; Liu et al., 2019) warranting further 
investigation of possible causal effects. Prospective observational studies using related 
individuals to control for genetic and environmental confounding have suggested a dose-
response effect of smoking on schizophrenia (Kendler et al., 2015) and depression (Kendler 
et al., 1993). Meta-analyses show further evidence for an increased relative risk of 
schizophrenia in smokers over non-smokers (Gurillo et al., 2015; Scott et al., 2018) and a 
reduction in depressive symptoms following smoking cessation (G. Taylor et al., 2014). 
Although these studies suggest a potential causal effect, more robust methods are required 
to triangulate evidence and allow for stronger causal inference (Munafò and Davey Smith, 
2018).  
One possible way to overcome bias from residual confounding and reverse causation 
is Mendelian randomisation (MR) (Davey Smith and Ebrahim, 2003). This method uses 
genetic variants to proxy for an exposure in an instrumental variable analysis to estimate the 
causal effect on an outcome (Lawlor et al., 2008). Previous MR studies have failed to show 
any clear evidence for an effect of smoking on depression (Bjørngaard et al., 2013; A. E. 
Taylor et al., 2014; Wium-Andersen et al., 2015) and show suggestive but inconclusive 
evidence for an effect of smoking on schizophrenia (Gage et al., 2017; Wium-Andersen et 
al., 2015). However, the genetic instruments for smoking used in these MR studies are 
limited, only capturing individual aspects of smoking behaviour and only having identified 
limited numbers of suitable genetic variants (Bjørngaard et al., 2013; Gage et al., 2017; A. E. 
Taylor et al., 2014; Wium-Andersen et al., 2015). Furthermore, any instrument for smoking 
heaviness requires stratifying samples into smokers and non-smokers. Stratification is not 
possible using the most common MR method; two-sample MR. In two-sample MR, SNP-
exposure and SNP-outcome effects are estimated in two independent samples and the 
effect sizes are obtained from GWAS summary statistics. Therefore, in this context 
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stratification is not possible because GWAS summary data do not provide individual level 
data regarding smoking status. 
 Here we improve upon previous MR studies of smoking and mental health in two 
ways: 1) by using an updated instrument for smoking initiation which comprises 378 single 
nucleotide polymorphisms (SNPs) (Liu et al., 2019) and 2) we develop a novel genetic 
instrument for lifetime smoking exposure that takes into account smoking status (i.e., ever 
and never smokers), and among ever smokers takes into account smoking duration, 
heaviness and cessation. This instrument can therefore capture smoking behaviours beyond 
initiation and can be used in unstratified samples of smokers and non-smokers. By using the 
results of these different MR analyses together and triangulating across multiple methods, 
we aim to determine whether the observational associations between smoking, 




Data Sources and Genetic Instruments 
Smoking Initiation. The most recent GWAS of smoking initiation from the GSCAN 
consortium identified 378 conditionally independent genome-wide significant SNPs in a 
sample of 1,232,091 individuals of European ancestry (Liu et al., 2019). The 378 SNPs 
explain 2% of the variance in smoking initiation (Liu et al., 2019). When smoking initiation 
was the outcome, summary statistics without 23andMe (N=599,289) were used.  
Lifetime Smoking. In order to capture smoking heaviness and duration as well as 
smoking initiation, we generated a lifetime smoking measure using data from the UK 
Biobank. The UK Biobank is a national health research resource of 502,647 participants 
aged 40-69 years, recruited from across the United Kingdom between 2006 and 2010 
(http://www.ukbiobank.ac.uk). Our sample consisted of 462,690 individuals of European 
ancestry who had phenotype data and passed genotype inclusion criteria (54% female; 
mean age = 56.7 years; SD = 8.0 years). Overall, 30% of the sample had ever smoked (8% 
current smokers and 22% former smokers).  
 Measures of smoking. Smoking measures available in the UK Biobank were self-
reported and collected at initial assessment. They included: smoking status (current, former, 
never – field 20116), age at initiation in years (fields 3436/2867), age at cessation in years 
(field 2897) and number of cigarettes smoked per day (fields 3456/2887). Anyone self-
reporting to smoke more than 100 cigarettes per day was contacted for confirmation. Hand-
rolled cigarette smokers were told one gram of tobacco equates to one cigarette. We 
calculated duration of smoking and time since cessation. UK Biobank removed individuals 
smoking fewer than 1 or more than 150 cigarettes a day. 
 Construction of the lifetime smoking index. Following the method outlined by 
Leffondré and colleagues (2006), we combined the smoking measures into a lifetime 
smoking index along with a simulated half-life (τ) constant. Half-life captures the 
exponentially decreasing effect of smoking at a given time on health outcomes. The value of 
half-life was determined by simulating the effects of lifetime smoking on lung cancer and 
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overall mortality in the UK Biobank. Both suggested the best fitting value was 18. For full 
details on construction of the lifetime smoking index see Supplementary Note. 
 Genome-wide association study of lifetime smoking index. For full details of 
genotyping and exclusion procedures see Supplementary note. After excluding individuals 
who did not pass genotype exclusions and who had missing phenotype data, 462,690 
individuals remained for the GWAS. Of these individuals, 249,318 were never smokers 
(54%), 164,649 were previous smokers (36%) and 48,723 (11%) were current smokers. The 
mean value of lifetime smoking score was 0.359 (SD=0.694). GWAS was conducted using 
the UK Biobank GWAS pipeline set up for the MRC Integrative Epidemiology Unit (Elsworth 
et al., 2017). BOLT-LMM was used to conduct the analysis (Loh et al., 2015), which 
accounts for population stratification and relatedness using linear mixed modelling. 
Genotyping chip and sex were included as covariates. As a sensitivity analysis, we reran the 
GWAS without controlling for genotype chip because the UK BiLEVE sub-sample (which 
used a different genotyping chip) were selected on the basis of smoking status. Genome-
wide significant SNPs were selected at P < 5 × 10-8 and were clumped to ensure 
independence at linkage disequilibrium (LD) r2 = 0.001 and a distance of 10,000 kb using the 
TwoSampleMR package (Hemani et al., 2018). 
 Instrument generated. Our GWAS of lifetime smoking identified 126 independent, 
genome-wide significant SNPs (see Figure 1 and Supplementary Table S1). A standard 
deviation increase in lifetime smoking score is equivalent to an individual smoking 20 
cigarettes a day for 15 years and stopping 17 years ago or an individual smoking 60 
cigarettes a day for 13 years and stopping 22 years ago. We validated our instrument in an 
independent sample and using positive control outcomes of lung cancer, coronary heart 
disease and hypomethylation at the aryl-hydrocarbon receptor repressor (AHRR) site 
cg05575921 because smoking has been robustly shown to predict these outcomes (WHO, 
2011; Zeilinger et al., 2013). For further details of these validations see the Supplementary 
Note.  
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 Schizophrenia. We used summary data from the PGC consortium GWAS, which 
comprises 36,989 cases and 113,075 controls of European and East Asian ancestry (Ripke 
et al., 2014). Cases were a combination of individuals with schizophrenia and schizoaffective 
disorder, mostly diagnosed by clinicians, but some samples used research-based 
assessment. Ascertainment method did not affect GWAS results (Ripke et al., 2014). A 
sensitivity analysis was performed using the GWAS summary data meta-analysed with a 
further 11,260 cases and 24,542 controls (Pardiñas et al., 2018). The genetic instrument for 
schizophrenia came from the PGC GWAS, which identified 114 independent SNPs at 108 
loci explaining around 3.4% of the variance in schizophrenia liability (Ripke et al., 2014). 
Depression. For depression, we used GWAS summary data from the PGC for major 
depression, which comprises 130,664 major depression cases and 330,470 controls of 
European ancestry (Wray et al., 2018). Cases were either diagnosed with major depressive 
disorder (MDD) on inpatient or medical health records or self-reported having a diagnosis or 
treatment for depression. Therefore, the authors use the term major depression over 
diagnosed MDD (Wray et al., 2018). 23andMe data (75,607 cases and 231,747 controls) 
were excluded when major depression was the outcome because genome-wide summary 
statistics are not available with 23andMe data included. The genetic instrument for major 
depression from the PGC GWAS was 40 genome-wide significant SNPs which explain 1.9% 
of the variance in liability (Wray et al., 2018). 
 
Statistical Analysis 
 MR analyses were run using the MR Base R Package (Hemani et al., 2018; R. Core 
Team, 2014) and compared across five different methods: inverse-variance weighted, MR 
Egger (Bowden et al., 2015), weighted median (Bowden et al., 2016a), weighted mode 
(Hartwig et al., 2017) and MR RAPS (Zhao et al., 2018). Each of these methods makes 
slightly different assumptions about the nature of pleiotropy and therefore a roughly 
consistent point estimate across the multiple methods provides the strongest evidence of 
causal inference (Lawlor et al., 2016), with the IVW method being the main analysis and 
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each other method providing a sensitivity analysis. For additional details on each of the 
methods see Supplementary Table S12. Two-sample MR analysis was run bi-directionally, 
first with smoking as the exposure and then as the outcome. To test the suitability of the MR 
Egger method, the I2GX statistic was calculated to quantify the degree of regression dilution 
bias due to measurement error of SNP-exposure effects (Bowden et al., 2016b). We also 
calculated the mean F statistic as an indicator of instrument strength. Steiger filtering was 
conducted to confirm the direction of effect (Hemani et al., 2017). If a SNP from the 
instrument was unavailable in the outcome, an attempt to find proxies was made with a 
minimum LD r2 = 0.8 and palindromic SNPs were aligned with MAF<0.3. 
 
Results  
Bi-directional MR analyses provided strong evidence that increased lifetime smoking 
increases risk of both schizophrenia (IVW: OR = 2.27, 95% CI = 1.67 - 3.08, P < 0.001) and 
depression (IVW: OR = 1.99, 95% CI = 1.71 - 2.32, P < 0.001) (see Table 1), with consistent 
direction of effect across all five MR methods. The same was seen for smoking initiation as 
the instrument on schizophrenia (IVW: OR=1.53, 95% CI = 1.35 - 1.74, P < 0.001) and 
depression (IVW: OR=1.54, 95% CI = 1.44 - 1.64, P < 0.001) (See Table 1). MR Egger 
results are the least reliable due to low I2GX (see Supplementary Table S3). There was also 
evidence of a consistent but smaller effect of higher genetic liability for schizophrenia on 
lifetime smoking (IVW: β= 0.022, 95% CI = 0.005 - 0.038, P = 0.009) and of genetic liability 
for depression on lifetime smoking (IVW: β= 0.091, 95% CI = 0.027 - 0.155, P = 0.005) (see 
Table 2). These effects remained for depression on smoking initiation (IVW: β=0.083, 95% 
CI = 0.039 - 0.127, P < 0.001) but became even weaker and inconsistent across the different 
methods for schizophrenia on smoking initiation (IVW: β=0.010, 95% CI = 0.000 - 0.021, 
P=0.04) (see Table 2). Overall, the effect was larger and more consistent for depression 
than for schizophrenia. We saw similar effects using the more recent meta-analysed GWAS 
for schizophrenia with an additional 11,260 cases (see Supplementary Table S9). There was 
evidence of significant heterogeneity (see Supplementary Table S4) but MR Egger 
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intercepts suggest directional pleiotropy is not biasing the estimates (see Supplementary 
Table S5) and Steiger filtering supported the conclusion that the effects operate in both 
directions (see Supplementary Table S6). Given that variants from the CHRNA5-A3-B4 gene 
complex were identified in both GWAS of lifetime smoking and schizophrenia, we conducted 
a sensitivity analysis removing these variants and the effects remained consistent (see 
Supplementary Table S10).  
A total of 14,260 cases and 15,480 controls from the UK Biobank were included in 
the latest GWAS for major depression (Wray et al., 2018) which could lead to bias from 
sample overlap (Burgess et al., 2015). Therefore, this analysis was repeated using summary 
data from an earlier GWAS of major depression (Ripke et al., 2013), which showed a 
consistent direction of effect with weaker statistical evidence, possibly due to reduced 
sample size (N = 18,759) (see Supplementary Table S7). Second, we repeated this analysis 
with the recent meta-analysed GWAS which includes broader definitions of depression 
including self-declared (Howard et al., 2019).  These summary data were available with UK 
Biobank and 23andMe removed leaving a sample size of 500,199 (170,756 cases and 
329,443 controls). The results of this analysis are presented in Supplementary Table S11. 
They are relatively consistent with the main analysis, showing slightly larger effects of 
depression on smoking and slightly reduced effects of smoking on depression. Bi-directional 
MR analyses were repeated using the GWAS of lifetime smoking without controlling for 
genotyping chip and the same pattern of results was observed (see Supplementary Table 




 We conducted a GWAS of lifetime smoking exposure which provides a novel genetic 
instrument that can be used in two-sample MR of summary data without the need to stratify 
on smoking status. We used this novel genetic instrument along with a new instrument of 
smoking initiation to explore possible causal pathways between smoking, schizophrenia and 
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depression. The two-sample MR results provide strong evidence that smoking is a risk factor 
for both schizophrenia and depression. This supports prospective observational evidence 
controlling for genetic confounding (Kendler et al., 2015, 1993), as well as meta-analyses of 
observational studies (Gurillo et al., 2015; G. Taylor et al., 2014) (although it should be noted 
that these meta-analyses include estimates not adjusted for known confounders, for 
example, cannabis use). Effect sizes were similar to a more recent meta-analysis that did 
adjust for multiple confounders and found a two-fold increased risk of schizophrenia in 
smokers compared with non-smokers (Scott et al., 2018). Some studies which adjust for 
potential confounders find the effect of smoking attenuates to the null (Jones et al., 2018) or 
even becomes protective (Zammit et al., 2003), demonstrating that there are likely to be 
substantial confounding effects in observational studies. Previous MR studies have not 
found clear evidence to support smoking as a risk factor for either schizophrenia or 
depression (Bjørngaard et al., 2013; Gage et al., 2017; A. E. Taylor et al., 2014; Wium-
Andersen et al., 2015), but our approach offers greater power, captures multiple aspects of 
smoking behaviour and enables two-sample MR analysis using summary data in unstratified 
samples. However, it is not possible to precisely estimate from our results what proportion of 
the observational association between smoking, schizophrenia and depression is causal, or 
the population attributional fraction of these disorders due to smoking.  
In support of the self-medication hypothesis (Khantzian, 1997), we found evidence to 
suggest that genetic liability for schizophrenia and depression increases lifetime smoking. 
This supports previous observational evidence (Desai et al., 2001; Lerman et al., 1996; 
Levin et al., 1996) and might explain why smoking rates remain so high amongst individuals 
with schizophrenia and depression compared with the general population (Cook et al., 
2014). However, the evidence was stronger for self-medication effects in depression than 
schizophrenia and when using smoking initiation as the outcome rather than lifetime 
smoking, effects attenuated to the null. Therefore, maybe any self-medication effects of 
schizophrenia are only on heaviness and duration of smoking (captured by the lifetime 
smoking index) rather than initiation. However, it is important to note that the effects might 
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be weaker because MR methods typically capture the long-term effects of exposures 
(Labrecque and Swanson, 2018) with self-medication potentially being more acute.   
The effects of schizophrenia and depression on lifetime smoking might be explained 
by the misattribution hypothesis. This proposes that smokers misattribute the ability of 
cigarettes to relieve withdrawal, to their ability to relieve symptoms of psychological distress 
(Parrott, 2003, 1999).  For example, withdrawal symptoms include depressed mood, anxiety 
and irritability, and smoking a cigarette alleviates those symptoms (Hughes, 2007). Since 
many withdrawal symptoms are similar to the negative symptoms of schizophrenia and 
mood symptoms in depression, their alleviation by smoking could give rise to the strong 
belief that smoking helps to alleviate mental health symptoms.  
A potential biological mechanism for the bi-directional causal effects of smoking, 
schizophrenia and depression could be neuroadaptations in the dopaminergic and serotonin 
systems. Nicotine acts on nicotinic cholinergic receptors in the brain stimulating the release 
of neurotransmitters including dopamine and serotonin (Benowitz, 2010). Dopamine and 
serotonin dysfunction have been implicated in the aetiology of schizophrenia and depression 
respectively (Howes et al., 2015; Jakubovski et al., 2015). It is plausible, therefore, that 
disruption of these pathways has a causal effect on these disorders. Alternatively, cannabis 
use could be a mediating mechanism for the effects of smoking on schizophrenia and 
depression. In prospective studies, cigarette smoking has been shown to increase risk of 
cannabis dependence (Hindocha et al., 2015). There is strong evidence suggesting that 
cannabis use increases the risk of psychosis and affective disorders (Moore et al., 2007). 
This vertical pleiotropy does not violate the assumptions of MR, but simply means there are 
intermediate mechanisms operating between the exposure and the outcome. However, the 
strong effects we observe for lifetime smoking suggest that any mediating influence of 
cannabis use is likely to only partially account for these effects, given the relatively low 
prevalence of cannabis use (e.g., annual prevalence in the UK of ~7% in 2010 (United 
Nations Office on Drugs and Crime (UNODC), 2011)). Multivariable MR analysis of tobacco 
and cannabis use would help resolve this question. 
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Finally, although we are using the method of Mendelian randomisation to provide 
stronger causal inference, the best evidence of a causal effect comes from many 
corroborating lines of evidence from studies designs with diverse assumptions  . Looking at 
our current results alongside previous literature, we conclude this strengthens evidence for 
an effect of smoking on increased risk of depression and schizophrenia. Future work should 
attempt to elucidate the underlying mechanisms with a hope to intervene, inform public 
health messages or further advance our knowledge on the aetiology of mental illness. In 
particular, it will be important to consider other constituents of tobacco smoke to determine 
whether it is exposure to nicotine or some other constituent that increases risk of 
schizophrenia and depression. This is particularly important in the context of the recent 
growth in electronic cigarette use.  
 
Strengths and Limitations 
 Our study is the first to generate a genetic instrument for lifetime smoking behaviour 
in a large sample, which allows the use of two-sample MR with summary data from 
unstratified samples to answer questions about the association between smoking and other 
health outcomes. However, there are some limitations which should be noted. First, there is 
evidence to suggest that even after seemingly controlling for population structure in GWAS 
of samples as large as the UK Biobank, coincident apparent structure remains (Haworth et 
al., 2018). This might confound the association between smoking and mental health, 
increasing the risk of false positives. As independent samples with adequate sample size 
become available, the influence of structure should be further explored. However, it is 
reassuring that our instrument predicted lifetime smoking in an independent replication 
sample, where such issues would not arise in the same manner.  
Second, sample overlap in two-sample MR can bias results towards the 
observational estimate (Burgess et al., 2015). There was some sample overlap between the 
major depression GWAS (Wray et al., 2018) and the UK Biobank (used to derive the lifetime 
smoking instrument and included in the smoking initiation GWAS) meaning that the effects 
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could be inflated. Therefore, a sensitivity analysis was conducted using a previous GWAS of 
major depression (Ripke et al., 2013) which showed the same direction of effect despite 
lower power. This gives us confidence in the bi-directional effects of smoking and 
depression, despite sample overlap. This sensitivity analysis also addresses recent 
concerns over the specificity of the most recent GWAS for major depression (Cai et al., 
2018). Comparing self-reported “seeking help for depression” with DSM diagnosed MDD 
yielded different results (Cai et al., 2018). However, the earlier GWAS of depression did use 
DSM diagnosed cases only (Ripke et al., 2013) and showed the same direction of effect 
despite lower power.  
Third, including multiple aspects of smoking behaviour could have introduced more 
potential for horizontal pleiotropy. The more diffuse the definition of smoking, the more 
lifestyle factors might be correlated, making it especially important to test for horizontal 
pleiotropy. We conducted multiple sensitivity analyses (which all make different and largely 
uncorrelated assumptions), and all demonstrated the same direction of effect. This increases 
our confidence that the results are not biased by pleiotropy. Furthermore, MR Egger 
intercepts did not show evidence of directional pleiotropy for schizophrenia or depression. 
However, further work should still attempt to understand the biological mechanisms 
underpinning the association in order to reduce the likelihood of pleiotropic effects.  
Fourth, schizophrenia and depression are disorders with an average age of onset 
around early to mid-adulthood (ONS,  2018.; WHO, 2018). Our measure of lifetime smoking 
was generated using participants in the UK Biobank aged over 40 years. Therefore, the 
causal pathway from smoking to schizophrenia and depression risk might initially seem 
unclear. However, we were not using participants’ smoking behaviour at age 40, but rather 
retrospective lifetime smoking behaviour from age at initiation. It is plausible that smoking 
behaviour in earlier life could increase risk of later mental health outcomes and exacerbate 
symptoms, consequently causing more smokers than non-smokers to seek a diagnosis. 
Furthermore, we saw consistent effects when using smoking initiation as the exposure. 
Individuals are more likely to initiate smoking prior to the average age at onset of 
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schizophrenia and depression, with 90% of individuals initiating before 18 years of age 
(Centers for Disease Control and Prevention, 2018). There has also been recent debate in 
the field about the interpretation of time varying exposures in MR and one way to minimise 
bias is to use average SNP effects on phenotype across time, as we have done here with 
our lifetime smoking instrument (Labrecque and Swanson, 2018). We recommend that 
future studies wishing to examine the effects of smoking on an outcome use multiple 
instruments for smoking behaviour with consistent evidence across multiple instruments 
providing the strongest evidence of a causal effect.  
Fifth, there is a high degree of zero inflation in the distribution of our lifetime smoking 
index scores with 54% of the sample being never smokers and therefore receiving a score of 
zero. We decided not to transform the variable given the desire to have interpretable effect 
sizes for MR and we decided not to exclude never smokers because our instrument is 
designed to be used in two-sample MR without the need to stratify into smokers and non-
smokers. Despite the zero inflation, we see similar effects for lifetime smoking and smoking 
initiation suggesting that this has not impaired the score. Sixth, the lifetime smoking score 
was simulated using all-cause mortality and lung cancer as outcomes. The pattern of 
association between smoking and lung cancer risk compared with risk for schizophrenia and 
depression is likely to be different. However, increased mortality amongst individuals with 
schizophrenia and depression is in large part due to smoking related mortality (Royal 
College of Physicians, 2013). The effects were modelled on all-cause mortality and lung 
cancer but no difference to the best fitting value of half-life was observed. We hope that 
using all-cause mortality as an outcome makes the lifetime smoking instrument broadly 
applicable to exploring multiple outcomes. Furthermore, the same effects are observed 
using smoking initiation as the exposure, which does not include the simulated variable. 
Finally, there is known selection bias in the UK Biobank sample, with participants 
being more highly educated, less likely to be a smoker and overall healthier than the general 
UK population (Munafo et al., 2017). Of the 9 million individuals contacted, only ~5% 
consented to take part (Munafo et al., 2017). Due to the lack of representativeness in the UK 
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Biobank sample, prevalence and incidence rates will not reflect underlying population levels 
and there is potential for collider bias. If both smoking and liability for schizophrenia and 
depression reduce the likelihood of participating in the UK Biobank, then this would induce a 
negative correlation between schizophrenia or depression and smoking. That is the opposite 
of the effects observed, suggesting our estimates may, if anything, be conservative.   
 
Conclusion 
In conclusion, we improved upon previous MR studies of smoking and mental health 
by using an updated instrument of smoking initiation and by developing a novel genetic 
instrument of lifetime smoking that can be used in two-sample MR of summary data without 
stratifying on smoking status or reducing power. In two-sample MR analysis, there was 
evidence of an effect between smoking and mental health in both directions; however, the 
self-medication effects were stronger for depression than schizophrenia. Strong effects of 
smoking as a risk factor emphasises the detrimental public health consequences of 
smoking, especially for mental health, and the need to reduce smoking prevalence not only 
to reduce the burden of physical illness, but also to reduce the burden of mental illness.  
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Figure 1. Manhattan plot of genome-wide association study lifetime smoking index (N = 462,690).  
 
[Figure 1 Here]  
 
The x-axis represents chromosomal position and the y-axis represents -log10 P-value for the association of each single nucleotide 
polymorphism (SNP) with the lifetime smoking index using an additive model and linear regression. The dashed line indicates the genome-wide 
level of significance (P < 5 × 10-8) and genome-wide significant SNPs are indicated in red. 
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Table 1. Two-sample Mendelian randomisation analyses of the effect of smoking exposure on schizophrenia and depression. 
 
Exposure Outcome Method N SNP OR (95% CI) P-value 
Lifetime Smoking Schizophrenia Inverse-Variance Weighted 125 2.27 (1.67, 3.08) 1.36 × 10-07 
  MR Egger (SIMEX) 125 4.59 (1.49, 14.11) 0.009 
  Weighted median 125 2.04 (1.57, 2.64) 8.21 × 10-08 
  Weighted mode 125 1.71 (0.69, 4.23) 0.25 
  MR RAPS 125 2.44 (1.84, 3.25) 9.30 × 10-10 
Lifetime Smoking Depression Inverse-Variance Weighted 126 1.99 (1.71, 2.32) 9.69 × 10-19 
  MR Egger (SIMEX) 126 1.09 (0.62, 1.92) 0.77 
  Weighted median 126 1.97 (1.65, 2.35) 3.00 × 10-14 
  Weighted mode 126 1.83 (1.19, 2.81) 0.007 
  MR RAPS 126 1.99 (1.70, 2.32) 2.76 × 10-18 
Smoking initiation Schizophrenia Inverse-Variance Weighted 371 1.53 (1.35, 1.74) 3.70 x 10-11 
  MR Egger (SIMEX) 371 1.35 (0.83, 2.22) 0.23 
  Weighted median 371 1.38 (1.23, 1.55) 3.44 x 10-08 
  Weighted mode 371 1.23 (0.74, 2.06) 0.42 
  MR RAPS 371 1.63 (1.45, 1.85) 4.46 x 10-15 
Smoking initiation Depression Inverse-Variance Weighted 370 1.54 (1.44, 1.64) 3.61 x 10-37 
  MR Egger (SIMEX) 370 1.36 (1.10, 1.67) 0.004 
  Weighted median 370 1.46 (1.35, 1.58) 4.62 x 10-21 
  Weighted mode 370 1.44 (1.10, 1.89) 0.008 
  MR RAPS 370 1.54 (1.44, 1.65) 1.31 x 10-35 
 
Note: Due to low regression dilution I2GX for lifetime smoking and smoking initiation (see Supplementary Table S3), MR Egger SIMEX estimates 











Table 2. Two-sample Mendelian randomisation analyses of the effect of schizophrenia and depression on smoking. 
 
Exposure Outcome Method N SNP Beta (95% CI) P-value 
Schizophrenia Lifetime Smoking Inverse-Variance Weighted 102 0.022 (0.005, 0.038) 0.009 
  MR Egger (SIMEX) - - - 
  Weighted median 102 0.015 (0.004, 0.026) 0.009 
  Weighted Mode 102 0.016 (-0.014, 0.045) 0.31 
  MR RAPS 102 0.018 (0.003, 0.032) 0.015 
Depression Lifetime Smoking Inverse-Variance Weighted 34 0.091 (0.027, 0.155) 0.005 
  MR Egger (SIMEX) - - - 
  Weighted median 34 0.100 (0.058, 0.141) 2.77 × 10-06 
  Weighted mode 34 0.109 (0.037, 0.182) 0.005 
  MR RAPS 34 0.078 (0.014, 0.141) 0.016 
Schizophrenia Smoking initiation Inverse-Variance Weighted 107 0.010 (0.000, 0.021) 0.04 
  MR Egger (SIMEX) 107 -0.030 (-0.093, 0.033) 0.35 
  Weighted median 107 0.003 (-0.006, 0.012) 0.53 
  Weighted Mode 107 -0.008 (-0.033, 0.017) 0.54 
  MR RAPS 107 0.008 (-0.002, 0.017) 0.11 
Depression Smoking initiation Inverse-Variance Weighted 34 0.083 (0.039, 0.127) 2.32 x 10-04 
  MR Egger (SIMEX) - - - 
  Weighted median 34 0.077 (0.042, 0.112) 1.55 x 10-05 
  Weighted mode 34 0.062 (0.007, 0.117) 0.03 
  MR RAPS 34 0.077 (0. 037, 0.117) 1.64 x 10-04 
 
Note: Due to low regression dilution I2GX (see Supplementary Table S3), MR Egger estimates could not be conducted apart from for the effect 
of schizophrenia on smoking initiation, where a weighted MR Egger SIMEX was conducted.  SIMEX = simulation extrapolation, MR RAPS = 
robust adjusted profile score. Smoking initiation scores are given in betas by GSCAN calculated from the meta-analysed z-score statistic by 
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Construction of the lifetime smoking index. 
We simulated values of two constants: half-life (�), and lag time (�). Together these 
constants capture the non-linear risk of smoking on health. Half-life captures the 
exponentially decreasing effect of smoking at a given time on health outcomes.   Lag time 
accounts for the observation that smokers are more at risk of certain diseases (e.g., lung 
cancer) immediately after stopping smoking than current smokers (Leffondré, 
Abrahamowicz, Siemiatycki, & Rachet, 2002). This is likely due to the prodromal 
consequences of disease being felt by the individual.  
 
Simulations were run for possible values of τ (between 2 and 50 varying in increments of 
1) and δ (between 0 and 5, varying in increments of 0.1) to find the best fitting model to 
explain the effects of lifetime smoking on lung cancer and all-cause mortality. Akaike 
information criterion (AIC) was used to select the best fitting model. The best fitting value for 
half-life was 18 for both lung cancer and all-cause mortality. We did not see any 
improvement of fit for changes in the value of lag time, therefore this was set to 0 as has 
been done previously (Lewer, McKee, Gasparrini, Reeves, & de Oliveira, 2017). This 
removes the effects of lag time from the model. These values were used to fit the final model 
which is: 
 
tsc* = max(tsc - δ, 0) 
dur* = max(dur + tsc - δ, 0) – tsc* 
lifetime smoking = (1 – 0.5dur*/τ) (0.5tsc*/τ) ln(int+1) 
 
…where τ = half-life, δ = lag time, int = cigarettes per day, tss = time started smoking, tsc = 
time since cessation, dur = duration of smoking (either age-tss for current smokers or [age-
tsc]-tss for former smokers). So, in our case, where δ = 0, tsc* = tsc and consequently, our 
lifetime smoking calculation can be simplified to: 
 
 lifetime smoking = (1 – 0.5dur/τ) (0.5tsc/τ) ln(int+1) 
 
Individuals who have never smoked and have no smoking exposure will have a value of 0. In 
our sample, values for smokers ranged from 0.007 (an individual who smoked 1 cigarette 
per day for 1 year) to 4.169 (an individual who currently smokes 140 a day and started 
 3 
smoking at age 11 years of age). Values of lifetime smoking were treated as continuous in 
subsequent analysis.    
 
Genotyping and exclusion procedure. 
UK Biobank participants provided blood samples at initial assessment centre. Genotyping 
was performed using the Affymetrix UK BiLEVE Axiom array for 49,979 participants and 
using the Affymetrix UK Biobank Axiom® array for 438,398 participants. The two arrays 
share 95% coverage, but chip is adjusted for in all analyses because the UK BiLEVE sample 
is over represented for smokers. Imputation and initial quality control steps were performed 
by the Wellcome Trust Centre for Human Genetics resulting in over 90 million single 
nucleotide polymorphisms (SNPs) and indels (Bycroft et al., 2017).  
 
Individuals were excluded if there were sex-mismatches between reported and 
chromosomal sex or aneuploidy (N=814). Individuals were restricted to European ancestry 
based on the first four principal components of population structure and related individuals 
were removed following MRC Integrative Epidemiology Unit filtering steps (Mitchell, Hemani, 
Dudding, & Paternoster, 2017). After excluding individuals who had withdrawn consent, 
463,033 of the participants remained (Mitchell et al., 2017). We restricted our analysis to 
autosomes only and used filtering thresholds for SNPs of minor allele frequency (MAF) 
>0.01 and info score (measure of imputation uncertainty) >0.8.  
 
Instrument discovery for lifetime smoking index 
The results of our GWAS of lifetime smoking (N = 462,690) are presented in Figure 1 and 
Supplementary Figure S1. The most strongly associated regions on chromosome 15 (in the 
CHRNA5-A3-B4 gene complex) and chromosome 9 (near the DBH gene) have been 
previously shown to be associated with smoking heaviness and cessation respectively 
(Furberg et al., 2010). We identified 10,415 SNPs at the genome-wide level of significance 
(P < 5 × 10-8). After clumping and filtering, 126 independent SNPs remained. A full list of 
these SNPs and their z-scored effect sizes can be found in Supplementary Table S1.  
 
Instrument validation – positive control outcomes 
We tested our genetic instrument using the positive controls of lung cancer, CAD and hWe 
conducted these analyses using GWAS summary data in a two-sample MR framework using 





Outcome GWAS samples for instrument validation. 
For lung cancer, we used the summary data from the ILCCO consortium GWAS, which 
comprises 11,348 cases and 15,861 controls of European ancestry (Wang et al., 2014). 
Lung cancer cases were classified by tumour type using either the International 
Classification of Diseases for Oncology (ICD-O) or the World Health Organisation (WHO) 
coding. Tumours with overlapping histologies were classified as mixed. Most samples in the 
GWAS meta-analysis only included adenocarcinomas (AD) or squamous carcinomas (SQ) 
but classification was different for each contributing cohort. The GWAS was run with a binary 
outcome, case control status for any primary lung cancer tumour. For more details see 
Wang et al. (2014)7.    
 
For CAD, we used the GWAS summary data from CARDIoGRAMplusC4D which comprises 
60,801 cases and 123,504 controls of mixed ancestry (CARDIoGRAMplusC4D Consortium 
& others, 2015). Case status was defined as any CAD diagnosis including myocardial 
infarction, acute coronary syndrome, chronic stable angina or coronary stenosis of >50%. 
This GWAS was conducted with a binary outcome of CAD cases compared with controls.  
 
We conducted a GWAS of AHRR (cg05575921) methylation in the Accessible Resource for 
Integrated Epigenomic Studies (ARIES) subset of ALSPAC (Relton et al., 2015). Genome-
wide DNA methylation profiling in ARIES was performed using the Illumina Infinium 
HumanMethylation450 BeadChip (450K) array for ~1000 mother-offspring pairs (Relton et 
al., 2015). For this analysis, we used methylation data derived from whole blood which was 
collected from mothers (846 smokers and non-smokers) when the index offspring were 
around 18 years of age. Methylation data were normalised in R with the wateRmelon 
package (Pidsley et al., 2013) using the Touleimat and Tost (Touleimat & Tost, 
2012)algorithm to reduce the non-biological differences between probes. As was done 
previously (Gaunt et al., 2016), AHRR methylation (cg05575921) was rank-normalised to 
remove outliers and regressed on the following covariates: age, the top ten ancestry 
principal components, bisulphite conversion batch and estimated white blood cell counts 
(using an algorithm based on differential methylation between cell types (Houseman et al., 
2012)). Residuals were then taken forward and SNP association effects were obtained in 
PLINK1.07 using exact linear regression. Full details of the GWAS methods used for AHRR 
locus methylation are described elsewhere (Relton et al., 2015). 
 
Two-sample Mendelian randomisation of positive controls.  
Analyses were conducted using MR Base, an R (R. Core Team, 2014) package for two-
sample MR (Hemani et al., 2018). We compared results across five different MR methods: 
 5 
inverse-variance weighted, MR Egger (Bowden, Davey Smith, & Burgess, 2015), weighted 
median (Bowden, Davey Smith, Haycock, & Burgess, 2016), weighted mode (Hartwig, 
Smith, & Bowden, 2017) and MR RAPS (Zhao, Wang, Hemani, Bowden, & Small, 2018). 
Each method makes different assumptions and therefore a consistent effect across multiple 
methods strengthens causal evidence (Lawlor, Tilling, & Davey Smith, 2016). If a SNP was 
unavailable in the outcome GWAS summary statistics, then proxy SNPs were searched for 
with a minimum LD r2 = 0.8. We aligned palindromic SNPs with MAF<0.3. 
 
Results. 
 We validated the genetic instrument for lifetime smoking exposure using two-sample MR of 
smoking on positive control outcomes: lung cancer, CAD and hypomethylation at the AHRR 
locus. All five MR methods indicated the expected direction of effect (see Table 1) increasing 
risk of disease outcomes and decreasing AHRR methylation, with the exception of the MR 
Egger SIMEX adjusted estimates for CAD. However, these should be interpreted with 
caution given the low I2GX (see Supplementary Table S2) (Bowden, Del Greco M, et al., 
2016). There was strong evidence of an effect of lifetime smoking on increased odds of lung 
cancer and CAD. There was weaker evidence of an effect on AHRR methylation, possibly 
due to lower power. Sensitivity analyses are presented in Supplementary Figures S2-S7. 
There was evidence of significant heterogeneity in the SNP-exposure effects (see 
Supplementary Table S3); however, tests of MR Egger intercepts generally indicated weak 
evidence of directional pleiotropy (see Supplementary Table S4), with the exception of CAD.  
 
Instrument validation – replication in an independent sample  
ALSPAC sample description and measures. 
To test prediction in an independent sample, we used 2,712 mothers from Avon Longitudinal 
Study of Parents and Children (ALSPAC). ALSPAC is a longitudinal birth cohort, which 
recruited 14,541 pregnant women between April 1991 and December 1992 with detailed 
descriptions reported elsewhere (Boyd et al., 2013; Fraser et al., 2012). The study website 
contains details of all the data that is available through a fully searchable data dictionary and 
variable search tool (www.bristol.ac.uk/alspac/researchers/our-data/). Self-reported 
measures of smoking status, age at initiation, age at cessation and cigarettes per day were 
collected from these women when their offspring were 18 years of age (mean mothers age = 
48 years, SD = 4.3).  
 
Statistical Analysis.  
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PLINK was used to generate a polygenic risk score in ALSPAC (Purcell et al., 2007). Linear 
regression was used to estimate the percentage variance of lifetime smoking explained by 
the polygenic score.  
 
Results. 
In the ALSPAC independent sample, the 126 SNPs explained 0.36% of the variance in 




Genetic correlations were first calculated between lifetime smoking, smoking initiation (Liu et 
al., 2019), depression (Wray, Sullivan, & others, 2018) and schizophrenia (Ripke et al., 
2014) using the summary statistics outlined in the main text. Full summary statistics were 
only available for depression and smoking initiation excluding 23andMe. Genetic correlations 
were calculated using the LD Score Regression software (Bulik-Sullivan et al., 2015). 
 
Results 
There was evidence of positive genetic correlations between both smoking phenotypes (rG = 
0.868, <0.001), between lifetime smoking and depression (rG = 0.404, p<0.001) and 
between lifetime smoking and schizophrenia (rG = 0.160, p<0.001). Genetic correlations 
between smoking initiation and mental health are reported elsewhere (Liu et al., 2019). 
There was a positive genetic correlation between smoking initiation and schizophrenia (rG = 

























The x-axis indicates the -log10 p-value expected under the null hypothesis and the y-axis 
represents the observed -log10 p-value. 
 
Testing inflation by population structure 
 
The QQ plot suggests evidence of inflation due to population stratification. To check this, we 
calculated the LD score intercept (1.051, SE = 0.0094) and mean chi-square statistic (1.907) 
which give an attenuation ratio of 0.056, minimal evidence of inflation. The pattern seen here 




Figure S2. Scatter plot of IVW and sensitivity analyses of lifetime smoking on 































Figure S3 shows evidence of an outlier, however this plot does not account for SE in the 




A radial MR analysis of lifetime smoking on lung cancer using first order weights and an 




1. rs10918701   
2. rs12244388   
3. rs329120 
4. rs6562474  




Outliers are usually removed in an incremental fashion, beginning with the largest. However, 
we can see from our leave-one-out analysis (see Figure S7) that the two largest outliers for 
both methods (rs10918701 and rs12244388  ) do not affect the estimate once removed.  
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The SNP with the largest effect is rs8042849, which is an intron variant of the HYKK gene, 




Figure S6. Leave-one-out effects of lifetime smoking on coronary artery disease using 





Figure S7. Leave-one-out effects of lifetime smoking on lung cancer using the 


















































































The SNP with the largest effect on smoking is from rs8042374 located in the CHRNA3 gene 
(known to be associated with Nicotine dependence (Munafò et al., 2012; Thorgeirsson et al., 
2008; Tobacco Consortium, 2010; Ware, van den Bree, & Munafò, 2011). However, 
removing this SNP did not remove the effect (see Supplementary Figure S18).  
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Table S1. SNPs associated with lifetime smoking index at the genome-wide level of 
significance (p<5x10-8) and clumped for independence at kb=10000 and r2=0.001, in 







NonEA EAF Beta SE p-value 
rs8042849 15 78817929 C T 0.342 0.028 0.002 1.80E-39 
rs113382419 9 1.36E+08 C A 0.889 -0.041 0.003 3.00E-37 
rs6011779 20 61984317 C T 0.191 0.028 0.003 2.30E-27 
rs9919670 11 1.13E+08 G A 0.612 -0.022 0.002 7.60E-27 
rs2890772 2 1.46E+08 G T 0.413 -0.020 0.002 2.10E-22 
rs35175834 15 47680815 G A 0.788 -0.024 0.002 4.60E-22 
rs12244388 10 1.05E+08 G A 0.661 -0.019 0.002 1.40E-19 
rs11783093 8 27425349 C T 0.839 0.023 0.003 1.20E-16 
rs11210229 1 73860028 A G 0.384 0.017 0.002 2.00E-16 
rs62155874 2 1.06E+08 A G 0.873 -0.024 0.003 5.20E-16 
rs10226228 7 32315613 A G 0.630 -0.016 0.002 2.00E-15 
rs6119897 20 31145415 G A 0.762 -0.018 0.002 3.60E-15 
rs2867112 2 651349 T G 0.835 0.021 0.003 4.80E-15 
rs986391 5 1.67E+08 G A 0.367 0.016 0.002 9.40E-15 
rs3742365 14 1.04E+08 T C 0.595 -0.016 0.002 2.50E-14 
rs2401924 7 1.15E+08 G C 0.502 0.015 0.002 2.70E-14 
rs7807019 7 1.18E+08 A G 0.540 -0.015 0.002 6.70E-14 
rs549845 1 44076469 G A 0.301 0.016 0.002 8.30E-14 
rs10922907 1 91193049 A T 0.451 0.015 0.002 3.00E-13 
rs7569203 2 45154418 A C 0.689 -0.016 0.002 7.40E-13 
rs17309874 11 27667236 G A 0.740 -0.016 0.002 9.70E-13 
rs6778080 3 49317338 T C 0.267 0.016 0.002 1.30E-12 
rs8042134 15 97514404 T G 0.541 -0.014 0.002 1.30E-12 
rs17576594 4 1.48E+08 G A 0.724 0.016 0.002 1.70E-12 
rs7766610 6 1.12E+08 C A 0.183 0.018 0.003 2.20E-12 
rs1922018 7 3560401 C T 0.364 0.014 0.002 3.00E-12 
rs7553348 1 75005067 G A 0.438 0.014 0.002 5.20E-12 
rs7528604 1 66407352 G A 0.566 0.014 0.002 5.70E-12 
rs329120 5 1.34E+08 C T 0.581 0.014 0.002 6.30E-12 
rs12623702 2 2.03E+08 A G 0.613 -0.014 0.002 7.70E-12 
rs13296519 9 1.28E+08 G T 0.606 -0.014 0.002 8.10E-12 
rs6935954 6 26255451 A G 0.421 0.014 0.002 8.20E-12 
rs4671357 2 60136176 T C 0.519 -0.014 0.002 1.10E-11 
rs3896224 10 1.06E+08 A G 0.585 0.014 0.002 1.10E-11 
rs326341 3 1.08E+08 G A 0.525 0.014 0.002 1.20E-11 
rs4391802 11 28674592 A G 0.707 0.015 0.002 1.40E-11 
rs72678864 4 1.12E+08 G A 0.829 0.018 0.003 1.60E-11 
rs112282219 11 46632809 G A 0.959 -0.033 0.005 3.80E-11 
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rs10879871 12 75380511 T G 0.343 -0.014 0.002 5.00E-11 
rs889398 16 69556715 C T 0.588 0.013 0.002 6.30E-11 
rs4473348 2 1.82E+08 A T 0.250 -0.015 0.002 6.40E-11 
rs1221148 9 1.22E+08 C G 0.587 0.013 0.002 7.30E-11 
rs317021 4 35418368 T A 0.814 -0.017 0.003 1.10E-10 
rs1933270 1 49977965 T G 0.364 0.013 0.002 1.50E-10 
rs8614 17 27588806 C A 0.817 -0.017 0.003 1.80E-10 
rs11255908 10 8802912 T G 0.743 -0.015 0.002 2.30E-10 
rs13153393 5 1.68E+08 A G 0.884 -0.020 0.003 2.50E-10 
rs2678670 2 1.04E+08 A T 0.486 0.013 0.002 3.10E-10 
rs7333559 13 1.01E+08 G A 0.212 0.015 0.002 3.20E-10 
rs76608582 19 4474725 C A 0.953 0.031 0.005 3.20E-10 
rs421983 3 84892866 T C 0.519 0.013 0.002 3.30E-10 
rs4543592 9 3014254 T C 0.520 -0.012 0.002 4.50E-10 
rs11948770 5 13246336 T C 0.768 -0.015 0.002 4.90E-10 
rs7039819 9 82430418 G A 0.427 0.013 0.002 5.10E-10 
rs10282292 7 1.11E+08 C T 0.362 0.013 0.002 5.90E-10 
rs2838834 21 46665208 C T 0.699 -0.013 0.002 6.30E-10 
rs624833 4 2881256 T G 0.695 0.013 0.002 6.60E-10 
rs62135536 2 44326028 C T 0.968 0.035 0.006 8.00E-10 
rs3811038 2 1.13E+08 T C 0.724 -0.014 0.002 8.90E-10 
rs359243 2 60475509 T C 0.393 -0.013 0.002 9.50E-10 
rs11768481 7 96629103 C A 0.666 0.013 0.002 9.90E-10 
rs6779302 3 16859710 G T 0.633 -0.013 0.002 1.20E-09 
rs35169606 8 9604066 T G 0.612 0.013 0.002 1.20E-09 
rs67596067 17 50333733 G A 0.649 -0.013 0.002 1.20E-09 
rs2675638 10 63576286 G A 0.581 0.012 0.002 1.30E-09 
rs75742406 11 17070365 G A 0.739 0.014 0.002 1.30E-09 
rs71367545 18 77576337 G A 0.791 -0.015 0.002 1.40E-09 
rs71627581 5 43161351 G A 0.889 0.019 0.003 1.60E-09 
rs13016665 2 57995348 C A 0.577 -0.012 0.002 1.80E-09 
rs369230 16 89645437 G T 0.308 -0.013 0.002 1.80E-09 
rs10052591 5 50812738 T C 0.573 0.012 0.002 2.10E-09 
rs3769949 2 1.66E+08 T A 0.528 -0.012 0.002 2.50E-09 
rs7155595 14 77502546 A C 0.674 -0.013 0.002 2.50E-09 
rs7077678 10 1.04E+08 C T 0.623 0.012 0.002 2.60E-09 
rs860326 14 57342912 C T 0.428 0.012 0.002 2.70E-09 
rs12202536 6 67475273 A G 0.513 -0.012 0.002 2.80E-09 
rs4814873 20 19616429 C T 0.767 0.014 0.002 2.90E-09 
rs147412694 21 40702786 G A 0.850 -0.017 0.003 2.90E-09 
rs9842947 3 1.57E+08 C T 0.326 -0.013 0.002 3.10E-09 
rs2894808 6 52861990 T A 0.922 -0.022 0.004 3.50E-09 
rs12708665 16 24728227 A G 0.285 -0.013 0.002 3.50E-09 
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rs202645 22 41798520 A G 0.203 -0.015 0.002 3.90E-09 
rs62098013 18 50863861 G A 0.640 -0.012 0.002 4.10E-09 
rs4957528 5 1.06E+08 A C 0.208 -0.015 0.002 4.20E-09 
rs1246265 9 86761745 T C 0.305 -0.013 0.002 4.20E-09 
rs6598539 15 99204483 T C 0.489 -0.012 0.002 4.50E-09 
rs13009008 2 1.74E+08 A G 0.328 0.012 0.002 4.60E-09 
rs17553262 10 92912773 A C 0.885 -0.018 0.003 5.30E-09 
rs7297175 12 56473808 T C 0.431 -0.012 0.002 6.60E-09 
rs245774 5 1.71E+08 A G 0.272 -0.013 0.002 7.40E-09 
rs6962772 7 99081730 A G 0.846 0.016 0.003 7.80E-09 
rs12481282 20 44761377 G C 0.722 -0.013 0.002 7.80E-09 
rs35343344 19 18471610 C A 0.733 0.013 0.002 8.80E-09 
rs6562474 13 67332812 C G 0.651 0.012 0.002 1.00E-08 
rs775758 3 77582005 A T 0.433 0.012 0.002 1.10E-08 
rs2062882 8 91839576 G A 0.587 -0.012 0.002 1.10E-08 
rs7519626 1 99514554 C T 0.324 0.012 0.002 1.20E-08 
rs9435340 1 1.08E+08 T A 0.344 0.012 0.002 1.20E-08 
rs34866095 11 16377356 A G 0.686 -0.012 0.002 1.20E-08 
rs348809 20 59032097 A G 0.348 -0.012 0.002 1.30E-08 
rs1050847 16 87443734 C T 0.426 0.011 0.002 1.40E-08 
rs73220544 3 1.31E+08 A C 0.842 -0.016 0.003 1.50E-08 
rs4571506 5 87756918 C T 0.540 0.011 0.002 1.50E-08 
rs732083 17 37834367 G A 0.333 0.012 0.002 1.50E-08 
rs6741228 2 22548774 T C 0.433 0.011 0.002 1.60E-08 
rs4949465 1 32178489 T C 0.870 -0.017 0.003 1.70E-08 
rs62175972 2 1.61E+08 T C 0.966 0.031 0.006 1.70E-08 
rs136233 22 31212410 A G 0.809 -0.014 0.003 1.80E-08 
rs12831617 12 84758368 C T 0.764 -0.013 0.002 1.90E-08 
rs11861214 16 746611 G T 0.784 0.014 0.002 2.00E-08 
rs10918701 1 1.62E+08 G A 0.372 0.012 0.002 2.10E-08 
rs10823968 10 74738269 A T 0.633 0.012 0.002 2.10E-08 
rs74086911 12 50015942 G A 0.925 0.021 0.004 2.10E-08 
rs4731925 7 1.33E+08 C T 0.316 -0.012 0.002 2.60E-08 
rs28485305 15 74044197 C T 0.631 0.012 0.002 2.60E-08 
rs1193237 1 7526486 G C 0.439 -0.011 0.002 2.80E-08 
rs60952428 16 75640521 T C 0.909 0.019 0.003 3.00E-08 
rs9904288 17 47031973 T C 0.708 0.012 0.002 3.10E-08 
rs12967855 18 35138245 A G 0.331 0.012 0.002 3.10E-08 
rs2254710 6 37477000 C A 0.236 0.013 0.002 3.50E-08 
rs72674867 8 95578201 A T 0.765 0.013 0.002 3.80E-08 
rs1931263 1 96175101 G T 0.510 -0.011 0.002 4.00E-08 
rs57611503 16 31165795 G A 0.485 0.011 0.002 4.00E-08 
rs61796681 4 23678196 A T 0.912 -0.019 0.004 4.20E-08 
 29 
rs6957896 7 1.32E+08 C T 0.503 -0.011 0.002 4.50E-08 
rs2080870 5 60388313 A T 0.258 0.012 0.002 4.90E-08 
 
Note. CHR = chromosome, BP = base position, EA = effect allele, Non EA = non-effect 


















































Table S2. Two-sample Mendelian randomisation analyses of the effect of lifetime 
smoking on coronary artery disease, lung cancer and AHRR Methylation. 
 
 
Of the 126 genome-wide significant SNPs associated with the lifetime smoking index, 126 
were available from the GWAS of coronary artery disease (Nikpay et al., 2015), 120 from the 
GWAS of lung cancer (Wang et al., 2014) and 119 from our GWAS of AHRR locus 
methylation. SIMEX-corrected estimates are unweighted. Due to low regression dilution I2GX 
(see Supplementary Table S3), MR Egger SIMEX estimates should be interpreted with 
caution and MR Egger estimates could not be calculated. SIMEX = simulation extrapolation, 


























Outcome Method OR (95% CI) P-value 
Coronary Artery 
Disease 
Inverse-Variance Weighted 1.56 (1.34, 1.82) 
1.19 × 10-08 
 MR Egger (SIMEX) 0.76 (0.44, 1.34) 0.35 
 Weighted Median 1.65 (1.36, 2.00) 5.40 × 10-07 
 Weighted Mode 1.79 (1.06, 3.03) 0.03 
 MR RAPS 1.63 (1.40, 1.90) 5.65 × 10-10 
Lung Cancer Inverse-Variance Weighted 4.21 (2.98, 5.96) 3.49 × 10-16 
 MR Egger (SIMEX) 16.64 (3.88, 71.42) 9.61 × 10-05 
 Weighted Median 2.77 (1.91, 4.03) 8.88 × 10-08 
 Weighted Mode 6.19 (2.07, 18.54) 0.001 
 MR RAPS 3.71 (2.75, 5.00) 8.65 × 10-18 
  Beta (95% CI) P-value 
AHRR Methylation Inverse-Variance Weighted -0.098 (-0.168, -0.028) 0.006 
 MR Egger (SIMEX) -0.176 (-0.443, 0.102) 0.217 
 Weighted Median -0.125 (-0.228, -0.021) 0.02 
 Weighted Mode -0.207 (-0.511, 0.097) 0.18 
 MR RAPS -0.095 (-0.171, -0.013) 0.01 
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I2GX Weighted mF 
Lifetime smoking > CAD 0.644 0.454 44.05 
Lifetime smoking > Lung cancer 0.643 0.340 44.36 
Lifetime smoking > AHRR methylation 0.635 0.455 44.08 
Lifetime smoking > Schizophrenia (2014) 0.634 0.405 44.08 
Lifetime smoking > Schizophrenia (Steiger 
filtered) 
0.667 0.441 44.25 
Lifetime smoking > Schizophrenia (2018) 0.642 0.417 44.27 
Lifetime smoking > Schizophrenia (CHRNA5 
removed) 
0.59 0.25 43.05 
Lifetime smoking > Depression (2018) 0.644 0.429 44.05 
Lifetime smoking > Depression (2018) (Steiger 
filtered) 
0.646 0.436 44.22 
Lifetime smoking > Depression (2013) 0 0 41.06 
Lifetime smoking > Depression (2019) 0.617 0.363 43.46 
Schizophrenia (2014) > Lifetime smoking 0.429 0 37.90 
Schizophrenia (2018) > Lifetime smoking 0.487 0 40.86 
Schizophrenia (CHRNA3 removed) > Lifetime 
smoking 
0.43 0 37.78 
Depression (2018) > Lifetime smoking 0 0 36.72 
Depression (2018) > Lifetime smoking (Steiger 
filtered) 
0 0 36.49 
Depression (2013) > Lifetime smoking 0.358 0 19.05 
Depression (2019) > Lifetime smoking 0.322 0.111 28.79 
Smoking initiation > Schizophrenia 0.603 0.401 44.98 
Smoking initiation > Depression (2018) 0.613 0.561 44.93  
Schizophrenia > Smoking initiation 0.422 0.762 37.62 
Depression (2018) > Smoking initiation 0 0 36.83 
 
CAD: coronary artery disease. Unweighted estimates only take into account dilution in the 
SNP-exposure effects, whereas weighted estimates account for the SE of the SNP-outcome 
effects(Bowden, Del Greco M, et al., 2016). The unweighted I2 estimates were larger for both 
positive control outcomes so in Table 1 (main text), unweighted MR Egger SIMEX estimates 
are presented. For the main analysis unweighted MR Egger SIMEX corrections are 
presented unless I2 estimates < 0.6 which is too low to conduct either MR Egger analysis. All 
estimates show evidence of high dilution in the SNP-exposure effects, so MR Egger 












Table S4. Tests of Heterogeneity in the SNP-exposure association 
  
Method Q df P-
value 
Lifetime smoking > CAD Inverse-variance weighted 184.72 125 <0.001 
 MR Egger 175.12 124 0.002 
 Q’ 9.60 1 0.002 
Lifetime smoking > Lung cancer Inverse-variance weighted 235.82 119 <0.001 
 MR Egger 228.96 118 <0.001 
 Q’ 6.87 1 0.009 





 MR Egger 121.35 117 0.37 
 Q’ 0.72 1 0.40 
Lifetime smoking > Schizophrenia Inverse-variance weighted 573.03 124 <0.001 
 MR Egger 571.23 123 <0.001 
 Q’ 1.81 1 0.18 
Lifetime smoking > Schizophrenia 
(2018) 
Inverse-variance weighted 592.94 121 <0.001 
 MR Egger 591.77 120 <0.001 
 Q’ 1.17 1 0.28 
Lifetime smoking > Schizophrenia 
(CHRNA5 variant removed) 
Inverse-variance weighted 566.23 123 <0.001 
 MR Egger 565.96 122 <0.001 
 Q’ 0.27 1 0.60 
Lifetime smoking > Depression 
(2018) 
Inverse-variance weighted 259.98 125 <0.001 
 MR Egger 256.69 124 <0.001 
 Q’ 3.29 1 0.07 
Lifetime smoking > Depression 
(2013) 
Inverse-variance weighted 33.014 33 0.46 
 MR Egger 33.07 32 0.41 
 Q’ 0.08 1 0.78 
Lifetime smoking > Depression 
(2019) 
Inverse-variance weighted 497.29 124 <0.001 
 MR Egger 488.88 123 <0.001 
 Q’ 8.41 1 0.003 
Schizophrenia > Lifetime smoking Inverse-variance weighted 773.92 101 <0.001 
 MR Egger 770.30 100 <0.001 
 Q’ 3.61 1 0.05 
Schizophrenia (2018) > Lifetime 
smoking 
Inverse-variance weighted 869.67 135 <0.001 
 MR Egger 864.25 134 <0.001 
 Q’ 5.42 1 0.20 
Schizophrenia (CHRNA3 variant 
removed) > Lifetime smoking 
Inverse-variance weighted 628.72 100 <0.001 
 MR Egger 622.49 99 <0.001 
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 Q’ 6.23 1 0.01 
Depression (2018) > Lifetime 
smoking 
Inverse-variance weighted 255.61 33 <0.001 
 MR Egger 250.29 32 <0.001 
 Q’ 5.32 1 0.02 
Depression (2013) > Lifetime 
smoking 
Inverse-variance weighted 59.75 36 0.008 
 MR Egger 59.48 35 0.006 
 Q’ 0.27 1 0.60 
Depression (2019) > Lifetime 
smoking 
Inverse-variance weighted 481.97 94 <0.001 
 MR Egger 481.77 93 <0.001 
 Q’ 0.20 1 0.66 
Smoking Initiation > 
Schizophrenia 
Inverse-variance weighted 1468.61 370 <0.001 
 MR Egger 1467.30 369 <0.001 
 Q’ 1.32 1 0.25 
Smoking Initiation > Depression 
(2018) 
Inverse-variance weighted 704.94 369 <0.001 
 MR Egger 699.86 368 <0.001 
 Q’ 5.07 1 0.02 
Schizophrenia > Smoking 
initiation 
Inverse-variance weighted 409.42 106 <0.001 
 MR Egger 402.35 105 <0.001 
 Q’ 7.06 1 <0.001 
Depression (2018) > Smoking 
initiation 
Inverse-variance weighted 153.61 33 <0.001 
 MR Egger 150.95 32 <0.001 
 Q’ 2.66 1 0.10 
Note: df = degrees of freedom where degrees of freedom is equal to the number of SNPs -1. 
Q = Rucker’s Q(Bowden et al., 2017), a test of heterogeneity or dispersion in the SNP-
exposure effects.  
The Q’ indicates the extent to which MR Egger is a better fit than the inverse-variance 




















Table S5. MR Egger test of directional pleiotropy 
 
Outcome Intercept (95% CI) P-value 
Lifetime smoking > CAD 0.012 (0.003, 0.022) 0.010 
Lifetime smoking > Lung cancer -0.021 (-0.042, -0.001) 0.062 
Lifetime smoking > AHRR methylation -0.001 (-0.004, 0.002) 0.406 
Lifetime smoking > Schizophrenia (2014) -0.006 (-0.025, 0.013) 0.531 
Lifetime smoking > Schizophrenia (2018) -0.004 (-0.022, 0.013) 0.627 
Lifetime smoking > Schizophrenia (CHRNA5 removed) -0.002 (-0.022, 0.017) 0.808 
Lifetime smoking > Depression (2018) 0.006 (-0.003, 0.015) 0.210 
Lifetime smoking > Depression (2013) 0.009 (-0.055, 0.073) 0.787 
Lifetime smoking > Depression (2019) 0.005 (-0.002, 0.012) 0.148 
Schizophrenia (2014) > Lifetime smoking 0.002 (-0.004, 0.007) 0.495 
Schizophrenia (2018) > Lifetime smoking 0.002 (-0.002, 0.006) 0.360 
Schizophrenia (CHRNA3 removed) > Lifetime smoking 0.002 (-0.002, 0.007) 0.32 
Depression (2018) > Lifetime smoking 0.006 (-0.008, 0.019) 0.416 
Depression (2013) > Lifetime smoking -0.001 (-0.004, 0.003) 0.693 
Depression (2019) > Lifetime smoking 0.0004 (-0.004, 0.005) 0.845 
Smoking initiation > Schizophrenia -0.003 (-0.013, 0.007) 0.565 
Smoking initiation > Depression (2018) 0.004 (-0,001, 0.010) 0.103 
Schizophrenia > Smoking initiation 0.002 (-0.001, 0.006) 0.177 
Depression (2018) > Smoking initiation 0.003 (-0.012, 0.006) 0.458 
 



























Table S6. Bi-directional two-sample Mendelian randomisation of lifetime smoking on schizophrenia and depression following Steiger 
filtering.  
 
Exposure Outcome Method N SNP OR (95% CI) p-value 
Smoking Schizophrenia Inverse-Variance Weighted 105/125 (84%) 1.73 (1.39, 2.16) 9.12 x 10-07 
  MR Egger (SIMEX)  6.19 (2.75, 13.95) 2.64 x 10-05 
  Weighted median  1.72 (1.34, 2.22) 2.78 x 10-05 
  Weighted mode  1.84 (0.73, 4.65) 0.20 
  MR RAPS  1.83 (1.45, 2.32) 3.97 x 10-07 
Smoking Depression Inverse-Variance Weighted 124/126 (98%) 1.94 (1.67, 2.25) 3.46 x 10-18 
  MR Egger (SIMEX)  1.17 (0.67, 2.04) 0.59 
  Weighted median  1.95 (1.65, 2.31) 4.70 x 10-15 
  Weighted mode  1.81 (1.17, 2.79) 0.008 
  MR RAPS  1.95 (1.68, 2.27) 3.81 x 10-18 
Exposure Outcome Method N SNP Beta (95% CI) p-value 
Schizophrenia Smoking - 102/102 (100%) - - 
Depression Smoking Inverse-Variance Weighted 32/34 (94%) 0.063 (0.007, 0.120) 0.028 
  MR Egger (SIMEX)  - - 
  Weighted median  0.084 (0.042, 0.126) 8.64 x 10-05 
  Weighted mode  0.111 (0.034, 0.187) 0.008 
  MR RAPS  0.065 (0.008, 0.123) 0.026 
 
Note: For each SNP in the instrument, Steiger filtering calculates how much of the variance the SNP explains in the exposure and how much it 
explains in the outcome. The number of SNPs which explain more variance in the exposure are presented in the N SNP column. Analysis is 
then repeated using only these SNPs to ensure that results are not due to reverse causation. For the effect of schizophrenia on lifetime 
smoking, all SNPs comprising the instrument for schizophrenia were better instruments for schizophrenia than lifetime smoking, therefore, that 
analysis was not repeated. All SIMEX corrections are unweighted due to greater unweighted I2GX (see Supplementary Table S2). Given low 









Table S7. Bi-directional two-sample Mendelian randomisation analyses of the effect of lifetime smoking on depression (2013).  
 
Exposure Outcome Method OR (95% CI) p-value 
Lifetime Smoking Depression Inverse-Variance Weighted 3.66 (2.08, 6.43) 6.46 x 10-06 
  Weighted median 3.69 (1.72, 7.94) 0.001 
  Weighted mode 3.18 (0.63, 16.06) 0.17 
  MR RAPS 4.23 (2.33, 7.67) 2.04 x 10-06 
Exposure Outcome Method Beta (95% CI) p-value 
Depression Lifetime Smoking Inverse-Variance Weighted 0.002 (-0.006, 0.011) 0.572 
  Weighted median 0.003 (-0.007, 0.012) 0.602 
  Weighted mode 0.002 (-0.016, 0.019) 0.844 
  MR RAPS 0.003 (-0.005, 0.012) 0.435 
 
Note: When depression is the exposure, a relaxed p-value threshold of p<5x10-5 was used because there were no SNPs associated at the 
genome wide level of significance. The direction of effect is consistent with the more recent GWAS for MDD despite sample overlap. There is 
weaker statistical evidence, possibly due to reduced sample size (N = 18 759). Both MR Egger and MR Egger (SIMEX) estimates could not be 



















Table S8. Bidirectional two-sample Mendelian randomisation analyses of the effect of lifetime smoking (from a sensitivity GWAS 
without chip as a covariate) on schizophrenia and major depression. 
 
Exposure Outcome Method N SNP OR (95% CI) P-value 
Lifetime Smoking Schizophrenia Inverse-Variance Weighted 137 2.23 (1.69, 2.95) 2.03 x 10-08 
  MR Egger (SIMEX) 137 3.71 (1.47, 3.39) 0.006 
  Weighted median 137 2.07 (1.61, 2.66) 1.24 x 10-08 
  Weighted mode 137 1.56 (0.63, 3.86) 0.34 
  MR RAPS 137 2.42 (1.86, 3.15) 6.09 x 10-11 
Lifetime Smoking Depression Inverse-Variance Weighted 90 1.88 (1.57, 2.24) 5.26 x 10-12 
  MR Egger (SIMEX) 90 4.39 (0.60, 323.15) 0.51 
  Weighted median 90 1.70 (1.39, 2.07) 1.53 x 10-07 
  Weighted mode 90 1.49 (0.99, 2.26) 0.06 
  MR RAPS 90 1.85 (1.55, 2.21) 9.00 x 10-12 
    Beta (95% CI) P-value 
Schizophrenia Lifetime Smoking Inverse-Variance Weighted 102 0.020 (0.003, 0.037) 0.02 
  MR Egger (SIMEX) 102 - - 
  Weighted median 102 0.008 (-0.004, 0.020) 0.19 
  Weighted Mode 102 0.004 (-0.027, 0.035) 0.80 
  MR RAPS 102 0.014 (-0.001, 0.030) 0.06 
Depression Lifetime Smoking Inverse-Variance Weighted 36 0.102 (0.036, 0.168) 0.002 
  MR Egger (SIMEX) - - - 
  Weighted median 36 0.101 (0.056, 0.147) 1.29 x 10-05 
  Weighted mode 36 0.124 (0.044, 0.204) 0.004 
  MR RAPS 36 0.091 (0.025, 0.157) 0.007 
 
Note: There were 139 genome-wide significant SNPs associated with lifetime smoking index when genotype chip was not included as a 
covariate in the GWAS. SIMEX-corrected estimates are unweighted. MR Egger regression was not conducted for schizophrenia or major 
depression as exposures because regression dilution I2GX was below 0.3 (see Supplementary Table S6). Due to low regression dilution I2GX for 
lifetime smoking as the exposure (see Supplementary Table S6), MR Egger and MR Egger SIMEX estimates should be interpreted with 






Table S9. Bi-directional two-sample Mendelian randomisation analyses of the effect of lifetime smoking on schizophrenia (2018).  
 
Exposure Outcome Method OR (95% CI) p-value 
Lifetime Smoking Schizophrenia Inverse-Variance Weighted 2.64 (1.99, 3.52) 2.36 x 10-11 
  MR Egger (SIMEX) 4.03 (1.38, 11.72) 0.01 
  Weighted median 2.23 (1.76, 2.82) 4.02 x 10-11 
  Weighted mode 2.20 (1.11, 4.36) 0.02 
  MR RAPS 2.74 (2.09, 3.58) 2.55 x 10-13 
Exposure Outcome Method Beta (95% CI) p-value 
Schizophrenia Lifetime Smoking Inverse-Variance Weighted 0.025 (0.011, 0.038) 0.0003 
  MR Egger (SIMEX) - - 
  Weighted median 0.016 (0.005, 0.026) 0.004 
  Weighted mode 0.029 (-0.011, 0.068) 0.159 
  MR RAPS 0.017 (0.004, 0.03) 0.009 
 
Note: MR Egger estimates could not be conducted due to low regression dilution I2GX (see Table S2). 
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Table S10. Bi-directional two-sample Mendelian randomisation analyses of the effect of lifetime smoking on schizophrenia with the 
CHRNA5-A3-B4 Variants removed  
 
Exposure Outcome Method N SNP OR (95% CI) p-value 
Lifetime Smoking Schizophrenia Inverse-Variance Weighted 124 2.19 (1.61, 2.99) 6.32 x 10-07 
  Weighted median 124 2.02 (1.57, 2.61) 6.23 x 10-08 
  Weighted mode 124 1.67 (0.85, 3.28) 0.14 
  MR RAPS 124 2.36 (1.77, 3.15) 5.53 x 10-09 
Exposure Outcome Method  Beta (95% CI) p-value 
Schizophrenia Lifetime Smoking Inverse-Variance Weighted 101 0.018 (0.003, 0.032) 0.02 
  Weighted median 101 0.015 (0.003, 0.026) 0.01 
  Weighted mode 101 0.016 (-0.012, 0.044) 0.28 
  MR RAPS 101 0.016 (0.003, 0.030) 0.02 
 
Note: This analysis was run using Ripke et al (2014) GWAS of schizophrenia. When lifetime smoking was the exposure, rs8042849 (located in 
the CHRNA5 gene was removed). This variant is in high LD (r2 = 0.83) with rs16969968, the variant previously associated with smoking 
heaviness (Furberg et al., 2010). When schizophrenia was the exposure, we removed rs8042374. This is located in the gene CHRNA3, part of 
the CHRNA5-A3-B4 gene complex which has been shown to affect nicotine intake and consequently smoking heaviness (Furberg et al., 2010). 
However, this particular variant is in low LD with rs16969968 (r2 = 0.18). Results were highly consistent with those including these two variants. 


















Table S11. Bi-directional two-sample Mendelian randomisation analyses of the effect of lifetime smoking on depression (Howard et 
al., 2019 with UKBB and 23andMe removed) 
 
Exposure Outcome Method N SNP OR (95% CI) p-value 
Lifetime Smoking Depression (2019) Inverse-Variance Weighted 125 1.63 (1.46, 1.83) 6.23 x 10-17 
  MR Egger (SIMEX) 125 0.89 (0.58, 1.37) 0.59 
  Weighted median 125 1.59 (1.43, 1.75) 3.06 x 10-19 
  Weighted mode 125 1.57 (1.15, 2.16) 0.006 
  MR RAPS 125 1.61 (1.44, 1.81) 9.14 x 10-17 
Exposure Outcome Method N SNP Beta (95% CI) p-value 
Depression (2019) Lifetime Smoking Inverse-Variance Weighted 95 0.165 (0.126, 0.204) 2.03 x 10-16 
  MR Egger (SIMEX) - - - 
  Weighted median 95 0.131 (0.099, 0.164) 1.69 x 10-15 
  Weighted mode 95 0.114 (0.035, 0.194) 0.006 
  MR RAPS 95 0.171 (0.133, 0.201) 7.13 x 10-19 
 
Note: This analysis has been conducted using the most recent PGC GWAS of depression (Howard et al., 2019) with the UK Biobank and 
23andMe samples removed. This is not the primary analysis given the less stringent definition of depression. However, the results are relatively 
consistent. Effects are smaller when depression is the outcome and slightly larger when depression is the exposure.  SIMEX correction for 
lifetime smoking as the exposure was unweighted due to greater unweighted I2GX (see Supplementary Table S2). Given low I2GX, all MR Egger 













Table S12. A comparison of each of the MR sensitivity analyses and their assumptions.  
 
Method Description Additional 
Assumptions 





weighted (IVW)  
A meta-analysis of the Wald ratios for each SNP (
����) 
weighted by the inverse of the variance of the SNP-
outcome association.  
Any horizontal 
pleiotropy must be 
balanced 
Has the most 
power if the 
assumptions 
are satisfied.  







(Bowden et al., 
2015) 
An extension of the IVW which relaxes the 
assumption that any pleiotropy must be balanced. A 
significant intercept term suggests bias from 
directional pleiotropy, i.e. the average pleiotropic 
effect is not zero. MR-Egger regression provides 
consistent estimates even if all genetic instrumental 
variables are invalid as long as the INSIDE 
assumption is met.  
InSIDEa 
NOMEb 
Has the lowest 
power 
100% ✗ ✓ 
Weighted median 
(Bowden, Davey 
Smith, et al., 
2016) 
The weighted median estimate is obtained by first 
calculating the Wald ratio causal estimate for each 
SNP and then taking the estimate with the median 
inverse variance weight.  
Consistent when 50% 
of weight contributed 
by genetic variants is 
valid. 
Similar to that of 
IVW method. 
50% ✓ ✓ 
Weighted mode 
(Hartwig et al., 
2017) 
Finds the largest cluster of Wald ratio estimates. The 
majority of the genetic instruments can be invalid 
providing the ZEMPA assumption is satisfied. In the 
weighted mode method, the mode is calculated using 
the inverse variance weights of the Wald ratios.  
ZEMPAc Less powerful 
than IVW and 
weighted 
median. 
50% ✓ ✓ 
Robust adjusted 
profile score 
(RAPS) (Zhao et 
al., 2018) 
An extension of IVW into a general framework which 
allows very many weak instruments. Requires no 
sample overlap in the exposure and outcome SNP 
effect estimates.  
InSIDEa 
Pleiotropy is additive.  
Pleiotropic effects are 
balanced (have mean 
zero).  
 100% ✓ ✓ 
 
Note. Where Z = the genetic instrument, X = the exposure and Y = the outcome. IV2 = assumption 2, that all instruments (Z) must not be 
associated with confounders. IV3 = assumption 3, that all instruments (Z) must only be associated with the outcome (Y) through the exposure 
(X). These two columns have a cross if that method requires the assumption to be met and a tick if that assumption can be relaxed. Throughout 
the table, invalid refers to instruments that do not meet the required assumptions for MR. Power of the methods might differ under different 
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models of pleiotropy.  aThe InSIDE assumption = pleiotropic effects of Z are independent of the effects of Z on the exposure. bThe no 
measurement error assumption (NOME) = assumes that the ZX associations are known, rather than estimated. cThe ZEMPA assumption = the 
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